Abstract 311P
Background
Endometrial cancer (EC) is the most common gynecological malignancy worldwide. Therefore, early diagnosis of EC is critical. Routine endometrial cytology has low sensitivity and specificity. If there are few endometrial cells and there are no obvious signs of atypia, knowledge of additional diagnostic criteria will help identify pathological processes in the endometrium. The aim of the study was to evaluate the diagnostic significance of serum cytokines in patients with EC and uterine myoma (UM).
Methods
The blood serum of primary patients with stage I (initial) EC (n=42) according to FIGO was studied. The mean age of patients was 37-77 years, and patients with UM (n=20) (41-59 years). The control group included 30 practically healthy female donors (23-65 years). The level of IL1RA, IL17A (Cytokin, Russia), IL1β, 2, 4, 6, 8, 10, 18, TNFα, IFNγ and MCP- 1 (VBV, Russia) in pg/ml. The results were expressed as IQRQ1-Q3. The study was carried out in accordance with the requirements of the Ethics Commission of the Institute of ME&PhC of UlSU. Statistical analysis was performed using Jamovi 1.6.5.0.
Results
A significant increase in the level of IL1RA in the blood serum of patients at stage I EC at UM (p=0.002) and relative to control (p=0.001). The concentration of circulating IL6 was significantly increased at initial EC compared with UM (p=0.044). MCP-1 in the serum of patients with UM is reduced compared with the control group (p=0.013). At stage I EC, the level of MCP-1 in serum is significantly higher compared with control (p=0.012) and UM (p=0.005). The levels of other cytokines did not show significant differences with the control group in the presented model. In a univariate logistic regression analysis for the differential diagnosis between UM and EC, statistical significance was jointly demonstrated by IL1RA and serum IL6/MCP-1 The risk of EC increases with concomitantly elevated serum levels of IL1RA and IL6 (R2=0.82, χ2=30.5, p=0.001) with a probability of 96.2% (Spec.=0.80, Sens.=0.96), as well as with simultaneously elevated levels of IL1RA and MCP-1 (R2=0.75, χ2=26.4, р=0.001) with 88.5% probability (Spec.=0.80, Sens.=0.88).
Conclusions
Evaluation of the serum level of IL1RA, IL6, MCP-1 can be used in the differential diagnosis of EC and UM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract